表紙
市場調査レポート

米国の血液がん治療薬市場とパイプライン分析

US Blood Cancer Drug Market & Pipeline Analysis 2015

発行 KuicK Research 商品コード 335661
出版日 ページ情報 英文 1100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
米国の血液がん治療薬市場とパイプライン分析 US Blood Cancer Drug Market & Pipeline Analysis 2015
出版日: 2015年07月22日 ページ情報: 英文 1100 Pages
概要

当レポートでは、米国の血液がん治療薬市場について調査分析し、発生率と有病率、市場の概要、市場の動向、臨床パイプライン、競合情勢などについて、体系的な情報を提供しています。

第1章 米国の血液がん発生率と有病率

  • 白血病
  • リンパ腫
  • 骨髄腫

第2章 米国の血液がん治療薬市場の概要

  • 現在の市場シナリオ
  • 米国の血液がん治療薬の臨床パイプラインの概要

第3章 米国の血液がん治療薬市場の動向

  • プラスに働く市場パラメーター
  • 商業化に向けた課題

第4章 米国の血液がん治療薬市場の将来見通し

第5章 血液がん治療薬の機序

第6章 白血病治療薬の臨床パイプライン:企業別、相別

  • 認証前研究
  • 中止・中断

第7章 上市済み白血病治療薬の臨床考察

第8章 リンパ腫治療薬の臨床パイプライン:企業別、相別

  • 認証前研究
  • 中止・中断

第9章 上市済みリンパ腫治療薬の臨床考察

第10章 多発性骨髄腫治療薬の臨床パイプライン:企業別、相別

  • 認証前研究
  • 中止・中断

第11章 上市済み多発性骨髄腫治療薬の臨床考察

第12章 多発性の血液がん治療薬の臨床パイプライン:企業別、相別

  • 認証前研究
  • 中止・中断

第13章 上市済み多発性の血液がん治療薬の臨床考察

第14章 競合情勢

  • Actelion Pharmaceuticals
  • Amgen
  • ARIAD Pharmaceuticals
  • Astellas Pharma
  • Baxter BioScience
  • Bayer HealthCare Pharmaceuticals Inc.
  • Biogen Idec
  • Bristol-Myers Squibb
  • CASI Pharmaceuticals
  • Celera Genomics Group
  • Celgene Corporation
  • エーザイ
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • Hospira
  • Johnson & Johnson
  • Millennium Pharmaceuticals
  • Nova Laboratories
  • Novartis
  • Onxeo SA
  • Onyx Pharmaceuticals
  • 大塚製薬
  • Pfizer
  • Roche
  • Scripps Clinic
  • Seattle Genetics
  • SRI International
  • Southern Research Institute
  • Tekmira Pharmaceuticals Corporation
  • Teva Pharmaceutical Industries
  • ヤクルト本社

図表

目次

Pharmaceutical companies have identified the opportunities to generate significant revenues from blood cancer segment in US. Escalating blood cancer incidences, high unmet medical necessities and demand for better therapeutics are some major factors behind growth of US blood cancer market segment. Higher investments have been made by pharmaceutical companies in order to come forth with better therapeutics for generating significant revenues. As a result, numerous therapeutic have been introduced in US market for the successful treatment of blood cancer. Several innovative therapeutics are at different stages of clinical trials which would be introduced in coming years.

Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs.

Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market.

Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase.

"US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights:

  • Blood Cancer Incidence & Prevalence
  • Blood Cancer Drug Market Overview
  • Blood Cancer Drug Market Dynamics
  • Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight
  • Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs
  • Majority Drugs in Phase-I Clinical Trials: 128 Drugs
  • Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis
  • Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs

Table of Contents

1. US Blood Cancer Incidence & Prevalence

  • 1.1. Leukemia: Cancer of White Blood Cells (WBC)
    • 1.1.1. Acute Lymphocytic Leukemia (ALL)
    • 1.1.2. Acute Myeloid Leukemia (AML)
    • 1.1.3. Chronic Lymphocytic Leukemia (CLL)
    • 1.1.4. Chronic Myeloid Leukemia (CML)
  • 1.2. Lymphoma: Cancer of Lymphatic System
    • 1.2.1. Hodgkin Lymphoma
    • 1.2.2. Non-Hodgkin Lymphoma (NHL)
  • 1.3. Myeloma

2. US Blood Cancer Drug Market Overview

  • 2.1. Current Market Scenario
  • 2.2. US Blood Cancer Drug Clinical Pipeline Overview

3. US Blood Cancer Drug Market Dynamics

  • 3.1. Favorable Market Parameters
  • 3.2. Commercialization Challenges

4. US Blood Cancer Drug Market Future Prospects

5. Mechanism of Blood Cancer Therapeutics

6. Leukemia Drug Clinical Pipeline by Company & Phase

  • 6.1. Research till Registered
  • 6.2. Discontinued & Suspended Leukemia Drug Clinical Insight

7. Marketed Leukemia Drug Clinical Insight

  • 7.1. Alemtuzumab (Campath®)
  • 7.2. Arsenic Trioxide (Trisenox®)
  • 7.3. Bosutinib (Bosulif®)
  • 7.4. Clofarabine
  • 7.5. Crisantaspase (Erwinaze®)
  • 7.6. Dasatinib (Sprycel®)
  • 7.7. Fludarabine (Fludara®)
  • 7.8. Idarubicin (Idamycin®)
  • 7.9. Imatinib (Gleevec®)
  • 7.10. Irinotecan
  • 7.11. Mercaptopurine Oral Suspension (Purixan™)
  • 7.12. Mitoxantrone (Novantrone®)
  • 7.13. Nilotinib (Tasigna®)
  • 7.14. Obinutuzumab (Gazyva®)
  • 7.15. Ofatumumab (Arzerra®)
  • 7.16. Omacetaxine Mepesuccinate (Synribo®)
  • 7.17. Pegaspargase (Oncaspar®)
  • 7.18. Pentostatin (Nipent®)
  • 7.19. Ponatinib (Iclusig®)
  • 7.20. Sargramostim (Leukine®)
  • 7.21. Tretinoin
  • 7.22. Vincristine Liposomal - Spectrum Pharmaceuticals (Marqibo®)

8. Lymphoma Drug Clinical Pipeline by Company & Phase

  • 8.1. Research till Registered
  • 8.2. Discontinued & Suspended Lymphoma Drug Clinical Insight

9. Marketed Lymphoma Drug Clinical Insight

  • 9.1. Belinostat (Beleodaq®)
  • 9.2. Bexarotene Oral (Targretin®)
  • 9.3. Bexarotene Topical (Targretin®)
  • 9.4. Brentuximab Vedotin (Adcetris®)
  • 9.5. Chlormethine (Valchlor™)
  • 9.6. Denileukin Diftitox (ONTAK®)
  • 9.7. Ibritumomab Tiuxetan (Zevalin®)
  • 9.8. Interferon Alpha-2b (Intron® A)
  • 9.9. Pralatrexate (Folotyn®)
  • 9.10. Romidepsin (Istodax®)
  • 9.11. Vorinostat (Zolinza®)

10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase

  • 10.1. Research till Preregistration
  • 10.2. Discontinued & No Development Reported in Multiple Myeloma Drug Clinical Insight

11. Marketed Multiple Myeloma Drug Clinical Insight

  • 11.1. Carfilzomib (Kyprolis®)
  • 11.2. Doxorubicin Liposomal - ALZA
  • 11.3. Pomalidomide (Pomalyst®)
  • 11.4. Thalidomide (Thalomid®)
  • 11.5. Zoledronic Acid (Zometa®)

12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase

  • 12.1. Research till Preregistration
  • 12.2. Discontinued & Suspended Multiple Blood Cancer Drug Clinical Insight

13. Marketed Multiple Blood Cancer Drug Clinical Insight

  • 13.1. Azacitidine (Vidaza®)
  • 13.2. Bendamustine (Treanda®)
  • 13.3. Bortezomib (Velcade®)
  • 13.4. Cladribine (Leustatin®)
  • 13.5. Decitabine (Dacogen®)
  • 13.6. Ibrutinib (Imbruvica®)
  • 13.7. Idelalisib
  • 13.8. Lenalidomide (Revlimid®)
  • 13.9. Nelarabine (Arranon®)
  • 13.10. Rituximab (Rituxan®)

14. Competitive Landscape

  • 14.1. Actelion Pharmaceuticals
  • 14.2. Amgen
  • 14.3. ARIAD Pharmaceuticals
  • 14.4. Astellas Pharma
  • 14.5. Baxter BioScience
  • 14.6. Bayer HealthCare Pharmaceuticals Inc.
  • 14.7. Biogen Idec
  • 14.8. Bristol-Myers Squibb
  • 14.9. CASI Pharmaceuticals
  • 14.10. Celera Genomics Group
  • 14.11. Celgene Corporation
  • 14.12. Eisai Co Ltd
  • 14.13. Genmab
  • 14.14. Gilead Sciences
  • 14.15. GlaxoSmithKline
  • 14.16. Hospira
  • 14.17. Johnson & Johnson
  • 14.18. Millennium Pharmaceuticals
  • 14.19. Nova Laboratories
  • 14.20. Novartis
  • 14.21. Onxeo SA
  • 14.22. Onyx Pharmaceuticals
  • 14.23. Otsuka Pharmaceutical
  • 14.24. Pfizer
  • 14.25. Roche
  • 14.26. Scripps Clinic
  • 14.27. Seattle Genetics
  • 14.28. SRI International
  • 14.29. Southern Research Institute
  • 14.30. Tekmira Pharmaceuticals Corporation
  • 14.31. Teva Pharmaceutical Industries
  • 14.32. Yakult Honsha

List of Figures

  • Figure 1-1: Main Types of Blood Cancer
  • Figure 1-2: Percentage of Leukemia in New Cancer Cases, 2015
  • Figure 1-3: Percentage of Leukemia in all Cancer Related Deaths, 2015
  • Figure 1-4: Leukemia Estimated Cases, 2013-2015
  • Figure 1-5: Leukemia Estimated New Cases in Males, 2013-2015
  • Figure 1-6: Leukemia Estimated New Cases in Females, 2013-2015
  • Figure 1-7: Leukemia Estimated Deaths, 2013-2015
  • Figure 1-8: Leukemia Estimated Deaths in Males, 2013-3015
  • Figure 1-9: Leukemia Estimated Deaths in Females, 2013-2015
  • Figure 1-10: Percentage of Acute Lymphocytic Leukemia in Cancer Related Deaths, 2015
  • Figure 1-11: Percentage of Acute Lymphocytic Leukemia in New Cancer Cases, 2015
  • Figure 1-12: Acute Lymphocytic Leukemia Estimated New Cases, 2013-2015
  • Figure 1-13: Acute Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015
  • Figure 1-14: Acute Lymphocytic Leukemia Estimated New Cases in Female, 2013-2015
  • Figure 1-15: Acute Lymphocytic Leukemia Estimated Deaths, 2013-2015
  • Figure 1-16: Acute Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015
  • Figure 1-17: Acute Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015
  • Figure 1-18: Acute Myeloid Leukemia Estimated New Cases, 2013-2015
  • Figure 1-19: Acute Myeloid Leukemia Estimated New Cases in Males, 2013-2015
  • Figure 1-20: Acute Myeloid Leukemia Estimated New Cases in Females, 2013-2015
  • Figure 1-21: Percentage of Acute Myeloid Leukemia in New Cancer Cases, 2015
  • Figure 1-22: Percentage of Acute Myeloid Leukemia in all Cancer Deaths, 2015
  • Figure 1-23: Acute Myeloid Leukemia Estimated Deaths, 2013-2015
  • Figure 1-24: Acute Myeloid Leukemia Estimated Deaths in Male, 2013-2015
  • Figure 1-25: Acute Myeloid Leukemia Estimated Deaths in Female, 2013-2015
  • Figure 1-26: Chronic Lymphocytic Leukemia Estimated New Cases, 2013-2015
  • Figure 1-27: Chronic Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015
  • Figure 1-28: Chronic Lymphocytic Leukemia Estimated New Cases in Females, 2013-2015
  • Figure 1-29: Chronic Lymphocytic Leukemia Estimated Deaths, 2013-2015
  • Figure 1-30: Percentage of Chronic Lymphocytic Leukemia in New Cancer Cases, 2015
  • Figure 1-31: Percentage of Chronic Lymphocytic Leukemia in all Cancer Related Deaths, 2015
  • Figure 1-32: Chronic Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015
  • Figure 1-33: Chronic Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015
  • Figure 1-34: Percentage of Chronic Myeloid Leukemia in New Cancer Cases, 2015
  • Figure 1-35: Percentage of Chronic Myeloid Leukemia in all Cancer Related Deaths, 2015
  • Figure 1-36: Categories of Chronic Myeloid Leukemia (CML)
  • Figure 1-37: Chronic Myeloid Leukemia Estimated New Cases, 2013-2015
  • Figure 1-38: Estimated New Cases of Chronic Myeloid Leukemia in Males, 2013-2015
  • Figure 1-39: Estimated New Cases of Chronic Myeloid Leukemia in Females, 2013-2015
  • Figure 1-40: Estimated Deaths due to Chronic Myeloid Leukemia, 2013-2015
  • Figure 1-41: Estimated Deaths due to Chronic Myeloid Leukemia in Male, 2013-2015
  • Figure 1-42: Estimated Deaths due to Chronic Myeloid Leukemia in Female, 2013-2015
  • Figure 1-43: Types of Lymphoma
  • Figure 1-44: Identification of Different Types of Lymphomas
  • Figure 1-45: Lymphoma Estimated New Cases, 2013-2015
  • Figure 1-46: Estimated New Cases of Lymphoma in Males, 2013-2015
  • Figure 1-47: Estimated New Cases of Lymphoma in Females, 2013-2015
  • Figure 1-48: Estimated Lymphoma Deaths, 2013-2015
  • Figure 1-49: Lymphoma Estimated Deaths in Males, 2013-2015
  • Figure 1-50: Lymphoma Estimated Deaths in Females, 2013-2015
  • Figure 1-51: Percentage of Hodgkin Lymphoma in New Cancer Cases, 2015
  • Figure 1-52: Percentage of Hodgkin Lymphoma in all Cancer Related Deaths, 2015
  • Figure 1-53: Estimated New Cases of Hodgkin Lymphoma, 2013-2015
  • Figure 1-54: Estimated New Cases of Hodgkin Lymphoma in Male, 2013-2015
  • Figure 1-55: Estimated New Cases of Hodgkin Lymphoma in Females, 2013-2015
  • Figure 1-56: Hodgkin Lymphoma Estimated Deaths, 2013-2015
  • Figure 1-57: Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015
  • Figure 1-58: Hodgkin Lymphoma Estimated Deaths in Female, 2013-2015
  • Figure 1-59: Percentage of Non-Hodgkin Lymphoma (NHL) in New Cancer Cases, 2015
  • Figure 1-60: Percentage of Non-Hodgkin Lymphoma in all Cancer Related Deaths, 2015
  • Figure 1-61: Non-Hodgkin Lymphoma Estimated New Cases, 2013-2015
  • Figure 1-62: Non-Hodgkin Lymphoma Estimated New Cases in Male, 2013-2015
  • Figure 1-63: Non-Hodgkin Lymphoma Estimated New Cases in Female, 2013-2015
  • Figure 1-64: Non-Hodgkin Lymphoma Estimated Deaths, 2013-2015
  • Figure 1-65: Non-Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015
  • Figure 1-66: Non-Hodgkin Lymphoma Estimated Deaths in Females, 2015- 2013
  • Figure 1-67: Percentage of Myeloma in New Cancer Cases, 2015
  • Figure 1-68: Myeloma Estimated New Cases, 2013-2015
  • Figure 1-69: Myeloma Estimated New Cases in Males, 2013-2105
  • Figure 1-70: Myeloma Estimated New Cases in Females, 2013-2015
  • Figure 1-71: Percentage of Myeloma in all Cancer Related Deaths, 2015
  • Figure 1-72: Myeloma Estimated Deaths, 2013-2015
  • Figure 1-73: Myeloma Estimated Deaths in Males, 2013-2015
  • Figure 1-74: Myeloma Estimated Deaths in Females, 2013-2015
  • Figure 2-1: Blood Cancer Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-2: Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-3: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-4: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-5: Discontinued Blood Cancer Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-6: Discontinued Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-7: Suspended Blood Cancer Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-8: Suspended Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-9: Leukemia Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-10: Leukemia Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-11: No Development Reported Leukemia Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-12: No Development Reported Leukemia Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-13: Discontinued Leukemia Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-14: Discontinued Leukemia Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-15: Suspended Leukemia Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-16: Suspended Leukemia Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-17: Lymphoma Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-18: Lymphoma Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-19: No Development Reported Lymphoma Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-20: No Development Reported Lymphoma Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-21: Discontinued Lymphoma Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-22: Discontinued Lymphoma Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-23: Suspended Lymphoma Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-24: Suspended Lymphoma Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-25: Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-26: Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-27: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-28: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-29: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-30: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-31: Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-32: Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-33: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-34: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-35: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-36: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
  • Figure 2-37: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
  • Figure 2-38: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
  • Figure 3-1: US Blood Cancer Drug Market Favorable Parameters
  • Figure 3-2: US Blood Cancer Drug Market Commercialization Challenges
  • Figure 5-1: Mechanism of Idelalisib
  • Figure 5-2: Mechanism of Imatinib
  • Figure 5-3: Mechanism of Rituximab
  • Figure 5-4: Mechanism of Doxorubicin
  • Figure 5-5: Mechanism of Carfilzomib
  • Figure 14-1: Actelion Pharmaceuticals Clinical Pipeline
  • Figure 14-2: Amgen Clinical Pipeline
  • Figure 14-3: ARIAD Clinical Pipeline
  • Figure 14-4: Casi Pharmaceutical Clinical Pipeline
  • Figure 14-5: Celgene Clinical Pipeline
  • Figure 14-6: Gilead Sciences Clinical Pipeline
  • Figure 14-7: GalaxoSmithKline Clinical Pipeline
  • Figure 14-8: Millennium Pharmaceuticals Clinical Pipeline
  • Figure 14-9: Novartis Clinical Pipeline
  • Figure 14-10: Onxeo SA Clinical Pipeline
  • Figure 14-11: Roche Clinical Pipeline
  • Figure 14-12: Tekmira Clinical Pipeline
Back to Top